Simon：Niki 你好呀，我們都有一段時間沒見了，今天也麻煩你啦，再和我們講講最近恆指以及個股方面的情況呀。我們不如先來講恆指方面 吧，這段時間你有沒有觀察到市場上的投資者有什麼動向呀？ 中銀董事Niki：是的，其實這段時間市場一下子又漲到了26000點附近的關口，所以看到投資者整體來說，都是用恆指的牛證、熊證來部署市場的波動為 主。目前來看，恆指牛證的重貨區集中在25100點到25200點左右，差不多接近1600張期指合約。也就是說，恆指牛證的整體加貨比例大概占63%，至於熊 證，大概占37%。可以看到牛證的比例還挺大的，所以這次投資者的看法都是希望市場能上漲呢。 在這方面，投資者都是用恆指的牛證、熊證來做部署，比如產品代碼方面，其實這兩天市場比較窄幅波動，都在26000點附近。比如恆指牛證的選擇，可以 留意64550這只恆指牛證，收回價在25800點左右，稍微有點近，但還是要看當時市場的位置。因為其實我們中銀國際的產品，差不多每50點到100點附近就 有一只產品，所以品類還挺齊全的。至於熊證方面，可以留意55898這只恆指熊證，收回價在26200點左右，槓桿大概有六十多倍。所以大家除了可以用恆指 的牛 ...

Group 1 - Jiangsu Hongxin's stock price increased by over 43%, reaching 4.80 HKD with a trading volume of 14.57 million HKD [1] - The company announced a placement of up to 21.42 million new shares, representing a 9.09% increase in post-expansion share capital, at a placement price of 2.90 HKD, which is a 13.95% discount to the closing price on November 11 [1] - The total fundraising amount is 62.13 million HKD, with a net amount of 58.65 million HKD intended for investment in Haike Hongxin [1] Group 2 - Haike Hongxin primarily engages in digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions development and application [1] - Its business scope also includes data processing, e-commerce, import and export, advertising, and related consulting and technical services [1] - The board believes that the placement will broaden the company's shareholder and capital base, and the net proceeds will strengthen the group's financial position for future development [1]

Core Viewpoint - Jiangsu Hongxin (02625) shares rose over 16%, reaching a price of HKD 3.93, with a trading volume of HKD 3.4448 million [1] Group 1: Share Placement - Jiangsu Hongxin announced a placement of up to 21.4246 million new shares, representing a 9.09% increase in the enlarged share capital [1] - The placement price is set at HKD 2.9, which reflects a discount of 13.95% compared to the closing price on November 11 [1] - The total amount raised from the placement is HKD 62.13 million, with a net amount of HKD 58.65 million intended for investment in Haike Hongxin [1] Group 2: Business Focus - Haike Hongxin primarily engages in digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions development and application [1] - Its business scope also includes data processing, e-commerce, import and export, advertising, and related consulting and technical services [1] Group 3: Financial Strategy - The board believes that the placement will broaden the company's shareholder and capital base [1] - The net proceeds from the placement will strengthen the group's financial position and prepare for future development [1]

Group 1 - The company Jiangsu Hongxin (02625.HK) has entered into a placement agreement to issue up to 21,424,691 new H shares at a price of HKD 2.90 per share, representing a discount of approximately 13.95% compared to the closing price of HKD 3.37 on the date of the agreement [1] - The placement shares will account for 10% of the company's existing share capital and approximately 9.09% of the enlarged share capital post-placement, assuming no changes in the issued share capital until the completion of the placement [1] - The estimated net proceeds from the placement, after deducting commissions and other expenses, are expected to be around HKD 58.65 million, equating to a net placement price of approximately HKD 2.737 per share [1] Group 2 - The net proceeds from the placement are intended to be fully invested in Haike Hongxin Digital Technology (Jiangsu) Co., Ltd., which focuses on digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions [2] - Haike Hongxin's business also encompasses data processing, e-commerce, import and export, advertising, and related consulting and technical services [2]

Robotics Industry Vision - The robotics industry envisions a future where humanoid robots can handle tasks currently performed by nannies, caregivers, and cleaners [1] - The industry anticipates that the mass production of humanoid robots could revolutionize factories, the service industry, and home life [1] - The industry speculates that humanoid robots could potentially eradicate poverty, provide superior medical technology, and even assist in crime prevention [1] Cost and Production - The robotics industry projects a target price of approximately $20,000 USD for a humanoid robot if annual production reaches 1 million units [1] - The industry forecasts a potential future production scale of 100 million units per year for humanoid robots [1] Potential Impact - The robotics industry suggests that even a 10% realization of the projected capabilities of humanoid robots could significantly transform the world [1]

Market Overview - The Hang Seng Index is expected to fluctuate around 26,000 points due to a hawkish stance from the Federal Reserve and ongoing uncertainties in the US-China trade relations [2] - The third quarter economic data from mainland China indicates further cooling, with a focus on expanding domestic demand and promoting technological self-reliance [2] Macro Focus - The Federal Reserve's direction for December rate cuts remains uncertain, with concerns about inflation among next year's voting members [4] - The Bank of England maintained its interest rate at 4%, with expectations for a potential rate cut in December [10] - Japan's major labor union is pushing for a 6% wage increase in the upcoming negotiations [10] Company News - Hua Hong Semiconductor (1347) reported a 43% decline in profit for the last quarter, but its fourth-quarter gross margin guidance exceeded expectations [11] - Uni-President China (0220) achieved a net profit of 2.01 billion RMB in the first three quarters, a year-on-year increase of 23.1% [11] - Da Jia Le (0341) anticipates a 65-70% drop in half-year profit due to a challenging market environment [11] - Great Wall Entertainment (1060) expects its mid-term net profit to exceed 500 million RMB, driven by strong performance in its Aliyu business [11] - Xiaomi (1810) has seen a 53% increase in short positions from institutional clients, indicating a bearish sentiment towards the stock [11] - Nissan (7201.JP) is selling its Yokohama headquarters for over $600 million as part of a 20-year leaseback agreement [11] - Xpeng Motors (2026) aims to achieve positive free cash flow by 2028, contingent on fleet expansion [11] - New World Development (0200) reported a 1.7 times increase in net income for the last quarter, attributed to improved performance in both gaming and non-gaming operations [11] Sector Insights - The insurance sector is benefiting from strong investment returns in the third quarter due to robust A-share performance [7] - AI concept stocks are gaining traction as mainland China accelerates the application of "Artificial Intelligence+" [7] - Coal stocks are expected to see upward price momentum for thermal coal [7]

Core Viewpoint - The company announced a non-binding memorandum of understanding with Hu Jian Yong to focus on developing advanced technologies in China, including IT services and artificial intelligence [1] Group 1: Partnership and Collaboration - The memorandum involves the establishment of a joint venture named Hu Zhong Zhi Suan Group Limited, aimed at leveraging resources and expertise in IT and AI services [1] - The parties intend to sign a formal joint venture agreement based on the terms of the memorandum and the actual development of the projects [1] Group 2: Business Expansion and Diversification - The board believes that the joint venture agreement will provide a framework for collaboration with Hu, facilitating the expansion of the company's construction business and promoting business diversification [1] - The terms of the joint venture agreement are based on normal commercial terms, deemed fair and reasonable, aligning with the overall interests of the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 HAO BAI INTERNATIONAL (CAYMAN) LIMITED 浩柏國際(開曼)有限公司 （ 於開曼群島註冊成立的有限公司） （ 股份代號：8431） 自願公告建議成立合營企業的諒解備忘錄 本公告乃由浩柏國際(開曼)有限公司(「本公司」，連同其附屬公司統稱「本集 團 」）自願作出，以向本公司股東及潛在投資者提供有關本集團最新業務發展 的消息。 合營企業協議諒解備忘錄 本公司董事（「董事 」）會（「董事會 」）欣然宣佈，本公司全資子公司中國 賓利投資有限公司近期與胡建勇先生（「胡先生 」，連同本公司統稱「訂約 方 」）訂立不具法律約束力的諒解備忘錄（「諒解備忘錄 」），內容涉及專注 於在中國建設開發中心、資訊技術服務及人工智慧領域，同時涵蓋雲端運算、 數位貨幣及數位產品開發等尖端技術。雙方擬共同設胡眾智算集團有限公司 （「合營公 司」）。 有關 胡建勇先 生的資料 胡建勇先生現任胡眾集團董事長 ...

IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 補充公告 (1)穩 定 幣 牌 照 申 請 進 度 更 新； (2)有 關 潛 在 加 密 貨 幣 購 買 的 重 大 收 購 事 項； (3)有 關 收 購 國 富 量 子 創 新 有 限 公 司 的 須 予 披 露 交 易 失 效；及 (4)進一步闡述本集團戰略發展方向 茲提述(i)華 檢 醫 療 控 股 有 限 公 司（「本公司」）於 二 零 二 五 年 七 月 十 七 日 刊 發 之 公 告、二 零 二 五 年 七 月 二 十 日 刊 發 之 有 關 戰 略 進 展 之 自 願 性 公 告；(ii)二 零 二 五 年 八 月 八 日 刊 發 之 自 願 性 公 告（「該公告」），內 容 有 關（其 中 包 括）本 集 團 推 出「ivd.xyz Exchange」－全 球 首 個 聚 焦 醫 療 創 新 藥NewCo高科技資產的真實世 界資產（「RWA」）交易所生態，以及「IVDD」穩定幣計劃。該計劃致力於通過「NewCo + RWA」Web3交 易 所 生 態 營 ...

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Abalone Bio aims to develop innovative obesity treatment drugs by targeting metabolic GPCRs, addressing current limitations in weight loss therapies and meeting unmet clinical needs globally [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a formal cooperation agreement with Abalone Bio to jointly advance the research and development of next-generation obesity treatment drugs [1] - The project focuses on enhancing energy expenditure safely and effectively while maintaining or increasing muscle mass, which is a significant challenge in current weight loss therapies [1] Group 2: Technical and Strategic Aspects - Abalone Bio will provide its core technology and platform support in GPCR antibody discovery, while Four Seasons will contribute its research and development resources in metabolic diseases and its established business framework in Greater China [2] - The collaboration is built on a prior strategic investment made by Four Seasons in Abalone earlier this year, marking a transition from capital investment to business execution [2] Group 3: Market Positioning and Future Prospects - This partnership strengthens Four Seasons' innovative positioning in the weight loss sector and accelerates the development of new weight loss and muscle gain therapies [2] - The collaboration is also a strategic move to deepen Four Seasons' involvement in the GPCR target area, following its investment in DJS Antibodies, which focuses on GPCR-targeted antibodies [2]